AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06281561
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Female patients undergoing hysteroscopy receive nasal spray with normal saline before anesthesia
Trial: NCT05297669
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo diluted to 100 ml with 0.9% sodium chloride injection. Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min).~One dose at 8h and 16h after the start of the first dose, the first intravenous infusion was started at 30±5 minutes before the end of the operation (Skin suture completes the last stitch).The drug was given 3 times,3 times/day, once every 8 hours.
Trial: NCT06394232
Drug: Eyecyte-RPE™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eyecyte-RPE™ is a suspension of hiPSCs (human induced Pluripotent Stem Cells) derived Retinal Pigment Epithelial Cells
Trial: NCT01938196
Drug: KWA-0711
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01938196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00063427
Drug: MAC-321
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04963764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive oral placebo for a standard course (10 days)
Trial: NCT06373523
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo pills will be manufactured to be identical in appearance to the study drug(Dapaglifozin 10 mg tablet).
Trial: NCT06373523
Drug: Levothyroxine Replacement daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine Replacement daily for 28 weeka
Trial: NCT05271552
Drug: BXCL501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual Film
Trial: NCT05271552
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual Placebo Film
Trial: NCT04811131
Drug: ARQ-252 cream 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARQ-252 cream 0.3%
Trial: NCT04811131
Drug: ARQ-252 Vehicle cream
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARQ-252 Vehicle cream
Trial: NCT05617430
Drug: HAIC
RxNorm normalized name: Hepatic Arterial Infusion Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h.~Q3W
Trial: NCT03678428
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin 200mg/m2 IV on Day 1 and 15.
Trial: NCT00992862
Drug: Univasc® 15mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05120076
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s. arm/group description
Trial: NCT05832697
Drug: Ursodeoxycholic Acid 250 Mg Oral Tablet
RxNorm normalized name: Ursodeoxycholic acid 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Ursodeoxycholic Acid 250 Mg Oral Tablet or Ursodeoxycholic Acid 100 Mg Oral Tablet
Trial: NCT05915871
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet for oral administration
Trial: NCT05468671
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil is an esterase-metabolized opioid
Trial: NCT05032144
Drug: STSA-1002 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection
Trial: NCT05032144
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection
Trial: NCT05256823
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be treated with Celecoxib twice daily for 48 weeks.
Trial: NCT05256823
Drug: nucleos(t)ide analogue
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will continue ongoing nucleos(t)ide analogue (Entecavir or Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Fumarate) therapy for 48 weeks
Trial: NCT06727617
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin: Administered by intravenous infusion during concurrent chemoradiotherapy at a dose of 30-40 mg/m² once weekly for only 5-6 treatment cycles; during sequential chemoradiotherapy, administered at 60-75 mg/m² on the first and second days of each cycle, once every 3 weeks (21 days) for only 4 treatment cycles.~Paclitaxel: Nab-paclitaxel administered by intravenous infusion at a dose of 135-175 mg/m² on the first day of each cycle, once every 3 weeks (21 days) for only 4 treatment cycles.
Trial: NCT04862260
Drug: Cholesterol metabolism disruption
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol metabolism disruption using a combination of atorvastatin, ezetimibe and evolocumab in metastatic pancreatic adenocarcinomas
Trial: NCT05814757
Drug: Collagen Punctal Plug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen Punctal Plug 0.2mm (Full Insertion)
Trial: NCT06213259
Drug: KD6005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological: KD6005, SQ
Trial: NCT06213259
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, SQ
Trial: NCT04818944
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline will be dosed for 24 hours post MT via continuous IV
Trial: NCT05269511
Drug: Chinese herbal medicine is in the form of granules (9 g/sachet), which is comprised of ten medicinal herbs.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration, twice per day.
Trial: NCT05581056
Drug: CFTR modulators
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Introduction of CFTR modulators by pneumologists for pneumologic issues
Trial: NCT01354184
Drug: CRD007
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06465472
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules will be administered for the first 6 months. Then patients will switch to stiripentol over the 6- to 12-month period.
Trial: NCT01354184
Drug: CRD007 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05700734
Drug: MK-8510
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of MK-8510 administered as a tablet at a dose up to 2200 mg.
Trial: NCT05633433
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04797650
Drug: CTP-543 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as tablets.
Trial: NCT05175781
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT05412004
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04644029
Drug: Placebo to FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg tablet administered once daily during Part 1.
Trial: NCT04644029
Drug: FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each tablet contains 200 mg emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300 mg tenofovir disoproxil fumarate or 201.22 mg tenofovir disproxil phosphate), administered orally once daily in Parts 1, 2, and 3.
Trial: NCT04644029
Drug: Placebo to ISL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg tablet administered orally once monthly in Part 1.
Trial: NCT04802616
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched tablets without any active substance.
Trial: NCT06147908
Drug: DW5221
FDA approved: no
EMA approved: no
PMDA approved: no
Description: megestrol acetate
Trial: NCT06147908
Drug: DW5221-R
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: megestrol acetate
Trial: NCT05156684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive two placebo tablets daily
Trial: NCT05156684
Drug: zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive one zinc sulfate tablet daily
Trial: NCT05156684
Drug: zinc + pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive two pentoxifylline tablets+ one zinc tablet daily
Trial: NCT05648799
Drug: GP30341 capsules 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orall take of capsules twice a day
Trial: NCT05648799
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medicines for treatment of a new coronavirus infection 2019 (COVID-19).
Trial: NCT05190627
Drug: Placebo 10mg/day added to rapamycin for 12 months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in the same type of capsule than the experimental drug
Trial: NCT06165432
Drug: Topical Benzocaine
RxNorm normalized name: benzocaine Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzocaine topical anesthetic gel will be used a pre-injection anesthetic on one half of the palate before giving greater palatine nerve block
Trial: NCT00057174
Drug: Disease management of gastroesophageal reflux disease
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR GASTROESOPHAGEAL REFLUX DISEASE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04282174
Drug: Hyperfractionated Total Body Irradiation
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperfractionated Total Body Irradiation is administered at a dose rate of \< 20 cGy/minute. Doses of 125 cGy/fraction are administered at a minimum interval of 4 hours between fractions, three times/day for a total of 11 or 12 doses (1375 or 1500 cGy) over 4 days (Day -9, -8, -7 and -6).
Trial: NCT04282174
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide: 60 mg/kg/day I V over approximately 30 min daily x 2 days (d -3 and -2). Cyclophosphamide dosing will be adjusted if patient is \> 125% of ideal body w eight and will be calculated based on adjusted ideal body weight, as per MCI standard of care guidelines.
Trial: NCT06258850
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One soft capsule will be administered once weekly for the first 12 weeks and one capsule every two weeks for the next 12 weeks.
Trial: NCT05478239
Drug: ArtemiCoffee
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cups of Artemisia annua (Aa) coffee per day (1350mg) for 24 weeks.
Trial: NCT05401565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT05603013
Drug: PD-1/PD-L1 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1/PD-L1 inhibitor subcutaneous injection or intravenous injection
Trial: NCT06452498
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule filled with cellulose.
Trial: NCT05299697
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks.
Trial: NCT04879017
Drug: FHD-286
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FHD-286 as a single agent
Trial: NCT06267092
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive subcutaneous (s.c.) injections of placebo matched to Cagrilintide and Semaglutide.
Trial: NCT06303505
Drug: TUB-040
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A complete treatment cycle is defined as 21 calendar days. TUB-040 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle
Trial: NCT05284344
Drug: Anti-Diabetics
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The anti-diabetic treatments include insulin glargine, insulin aspart, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, metformin, sulfonylureas and/or gliclazide. Therapeutic dose of each drug follows recommendation by the treating doctor.
Trial: NCT06069804
Drug: The TR group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miscible liquid of triamcinolone acetonide and ropivacaine in this study will be peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, 0.25ml triamcinolone acetonide (40mg/ml), plus 10 ml saline miscible liquids for participants who will undergo elective craniotomy. Local infiltration of the study solution was performed by the neurosurgeon after induction of general anesthesia and intubation, once all equipment and catheters had been placed, during stable and steady state anesthetic conditions before skin incision. The solution was infiltrated with a 22-gauge needle introduced into the skin at a 45° angle throughout the entire thickness of the scalp along the planned incision site and the head-holder sites, by the same neurosurgeon. The total volume of the study solution used for each patient was determined by the neurosurgeon mainly based on the length of the incision and recorded by the investigator.
Trial: NCT06069804
Drug: The R group
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, plus 10 ml saline miscible liquids for participants who will undergo elective craniotomy. Local infiltration of the study solution was performed by the neurosurgeon after induction of general anesthesia and intubation, once all equipment and catheters had been placed, during stable and steady state anesthetic conditions before skin incision. The solution was infiltrated with a 22-gauge needle introduced into the skin at a 45° angle throughout the entire thickness of the scalp along the planned incision site and the head-holder sites, by the same neurosurgeon. The total volume of the study solution used for each patient was determined by the neurosurgeon mainly based on the length of the incision and recorded by the investigator.
Trial: NCT05405439
Drug: TQB3823 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3823 tablet is an inhibitor of poly ADP-ribose polymerase (PARP).
Trial: NCT04984434
Drug: F182112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eight dose cohorts: 0.01, 0.1, 0.3, 1, 3, 10, 20 and 30 μg/kg) d1 treat every weeks.
Trial: NCT04789408
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT06444412
Drug: Ga 68 PSMA-11
RxNorm normalized name: Ga 68 PSMA-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast dye given IV
Trial: NCT06399679
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral placebo by mouth once, followed by placebo by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
Trial: NCT04871854
Drug: traditional Covid -19 therapy
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients treated with traditional therapy for Covid-19 infection
Trial: NCT05444569
Drug: LY3537021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT05444569
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT05353543
Drug: SSRIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this study, SSRIs antidepressants will be used, and the oral dose will be determined by the clinical specialist. Once-daily for 6 weeks.
Trial: NCT06401707
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05985863
Drug: standard medical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard medical treatment for ACLF
Trial: NCT05985863
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% human serum albumin in 0.9% saline (at week0, week1 and week2)
Trial: NCT05641181
Drug: CRB4101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the participants who signed the informed consent have been screened by the inclusion criteria, those who meet the inclusion criteria and those who do not meet the exclusion criteria will receive the following 6 dose groups in order from low to high:~100mg, 200 mg, 400 mg, 800 mg, 1200 mg, 1600 mg In each dose group, 8 participants will be enrolled to receive the drug, including 6 receiving CRB4101 tablets and 2 receiving placebo.
Trial: NCT05641181
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the participants who signed the informed consent have been screened by the inclusion criteria, those who meet the inclusion criteria and those who do not meet the exclusion criteria will receive the following 6 dose groups in order from low to high:~100mg, 200 mg, 400 mg, 800 mg, 1200 mg, 1600 mg In each dose group, 8 participants will be enrolled to receive the drug, including 6 receiving CRB4101 tablets and 2 receiving placebo.
Trial: NCT05564780
Drug: RASI and/or a single pill combination based RASI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants in the Treatment group will begin with a single category antihypertensive drug to control their blood pressure, for example, perindopril. If the blood pressure cannot be controlled under 130/80 mmHg, another type of antihypertensive drug will be added.
Trial: NCT05469646
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT04721535
Drug: DWJ1248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally, 1 tablet of DWJ1248 TID, up to 14 days
Trial: NCT04721535
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally, 1 tablet of placebo TID, up to 14 days
Trial: NCT05062759
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injection Q4W.
Trial: NCT06448273
Drug: TQB3702 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3702 tablets is administered as a single dose on day 1, or once daily on Days 1 to 7 on multiple dose. Dosage: 100mg, 150/200mg.
Trial: NCT06448273
Drug: TQB3702 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3702 placebo contains no active substance.
Trial: NCT05151705
Drug: HR17031 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group B: HR17031 injection; 10U/0.024mg
Trial: NCT05151705
Drug: HR17031 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group C: HR17031 injection; 10U/0.024mg
Trial: NCT06293742
Drug: ECC5004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECC5004 tablet will be administered orally.
Trial: NCT06293742
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin will be administered orally.
Trial: NCT05253495
Drug: DOC Group B
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 300 mg x1; dexamethasone x 7; vincristine x1
Trial: NCT05253495
Drug: Pv-R-CYM 1 and 2 Group B
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: polatuzumab vedotin x 1; methotrexate x 1; rituximab x 1; cytarabine x 5;
Trial: NCT05201092
Drug: [14C]-Lu AG06466
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]-Lu AG06466 will be administered per schedule specified in the arm description.
Trial: NCT00000638
Drug: Pyridoxine hydrochloride
RxNorm normalized name: Pyridoxine Hydrochloride
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05253495
Drug: Bv-AVD-R 1 and 2: COHORT IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brentuximab vedotin x 2; doxorubicin x 2; vinblastine x 2; dacarbazine 2x; rituximab x 2
Trial: NCT05253495
Drug: Bv-NVD-R, Cycle 1-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brentuximab vedotin x 2; nivolumab x 2; vinblastine x2; dacarbazine x 2; rituximab x 2;
Trial: NCT05253495
Drug: Bv-NVD-R, Cycle 1-4 SER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brentuximab vedotin x 2; nivolumab x 2; vinblastine x 2; rituximab x 2;
Trial: NCT05253495
Drug: Bv-AVD-R
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brentuximab vedotin x2; doxorubicin x2; vinblastine x 2; dacarbazine x 2; rituximab x2;